MacroGenics (MGNX) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

MGNX · Stock Price

USD 2.94+1.51 (+105.59%)

Market Cap: $190.7M

Historical price data

Overview

MacroGenics is a fully-integrated biopharmaceutical company with a mission to develop and commercialize life-changing, antibody-based cancer medicines. Its strategy is built upon a suite of proprietary technology platforms that generate a diverse pipeline of novel bispecific antibodies and ADCs, both for proprietary development and strategic partnerships. The company has advanced multiple candidates into clinical trials, retains economic rights to several partnered/commercialized assets, and maintains in-house GMP manufacturing capabilities to control its development destiny.

Oncology

Technology Platform

A proprietary suite of antibody engineering platforms including the DART® platform for bispecific antibodies, the TRIDENT® platform for trispecifics, an ADC platform for antibody-drug conjugates, and Fc optimization technology.

Pipeline

43

43 drugs in pipeline2 in Phase 3

Drug	Indication	Stage
Margetuximab + Trastuzumab + Physician's choice of chemother...	HER-2 Positive Breast Cancer	Phase 3
enoblituzumab + MGA012 + MGD013	Head and Neck Cancer	Phase 2/3
lorigerlimab + docetaxel + Prednisone	Androgen-Independent Prostatic Cancer	Phase 2
Enoblituzumab	Prostate Cancer	Phase 2
Lorigerlimab	Platinum-resistant Ovarian Cancer	Phase 2

Opportunities

Near-term clinical data from the Phase 2 lorigerlimab program and Phase 1 ADC candidates offer significant value inflection potential.

The partnered portfolio provides a steady stream of potential milestone and royalty revenue, while the proprietary technology platforms enable ongoing business development and collaboration opportunities.

Risk Factors

High clinical failure risk for lead assets in competitive oncology indications.

Dependence on future capital raises poses dilution risk.

Commercial success is uncertain given intense competition from larger, well-resourced pharmaceutical companies.

Competitive Landscape

MacroGenics competes in crowded fields for bispecific antibodies and ADCs against large-cap biopharma and other biotechs. Differentiation relies on demonstrating superior clinical profiles from its engineered platforms. Its integrated model provides an operational advantage over virtual peers.

More companies in Biologics / Biosimilars →More companies in United States →